The effect of somatostatin on GH-releasing factor (GRF)-induced desensitization of somatotrophs was studied in vitro. Primary cultures of rat anterior pituitary cells pretreated for 4 or 18 h with GRF(1\p=n-\40) (100 nmol/l) showed a 50% or greater reduction in maximal GH release when rechallenged with 10 nmol GRF/l. Rechallenge GRF dose\p=n-\response curves were either very flat, making accurate measurement of the dose giving 50% maximum stimulation (ED50) impossible, or the ED50 concentration was increased from 0\ m=. \ 3 nmol/l (untreated) to 2 nmol/l (GRF pretreated). Although GRF pretreatment reduced cellular GH content by 40\p=n-\50%, correction for this did not restore GRF responsiveness measured in terms of maximal GRF-stimulated/unstimulated GH release (maximal/basal ratio), or the GRF ED50 concentration. Maximal/basal GH release per 4 h from GRF-pretreated cells was reduced when cells were rechallenged with forskolin (5 \g=m\mol/l) or calcium ionophore (A23187; 10 \g=m\mol/l), to the same extent as when rechallenged with 10 nmol GRF/l. Although this might be explained by a reduction in the pool of releasable GH, an alternative explanation is that pretreatment with GRF disrupts the GH release mechanism(s) at a common step(s) beyond cyclic AMP generation and Ca2+ influx.
INTRODUCTION
Release of growth hormone (GH) is under dual con¬ trol from the hypothalamus in vivo: stimulatory through GH-releasing factor (GRF) (Rivier, Spiess, Thorner & Vale, 1982) and inhibitory through soma¬ tostatin (Brazeau, Vale, Burgus et al. 1973; Reichlin, 1983) . Somatostatin inhibits the GH-releasing action of GRF in vivo (Wehrenberg, Ling, Bohlen et al. 1982 ; (Harwood et al. 1984) . While GRF and somatostatin interact with somatotrophs through separate recep¬ tors (Srikant & Patel, 1982; Siefert, Perrin, Rivier & Vale, 1985) , the precise biochemical step(s) on which their separate interactions converge is not entirely clear, although cAMP generation is highly likely since this cellular signal is a major 'second messenger' for GRF action. Exposure of anterior pituitary cells to GRF renders somatotrophs partially or totally refrac¬ tory to subsequent rechallenge with the hormone, a process termed 'desensitization' which seems to be a common feature amongst the different anterior pituitary cell types (e.g. thyrotrophin-releasing hormone-thyrotroph; gonadotrophin-releasing hormone-gonadotroph). Desensitization, although des¬ cribed in animals in vivo (Wehrenberg, Brazeau, Ling et al. 1984) , is more readily observed in pituitary cells in vitro (Bilezikjian & Vale, 1984; Ceda & Hoffman, 1985) , though this has not been a universal finding (Diequez, Foord, Shewing et al. 1984) . This raises the possibility that a mechanism(s) exists in vivo whereby desensitization is partially or completely prevented.
Two recent studies in man lend support to this view.
It was observed that GH secretion was episodic dur¬ ing prolonged continuous infusion of GRF (Vance, Kaiser, Evans et al. 1985) or of an equipotent agonist analogue of GRF (Davis, Sheppard, Shakespear et al. 1986 ), rather than reaching a plateau and then steadily declining. Based on these findings it has been suggested (Vance et al. 1985; Davis et al. 1986) that GRF-stimulated GH release caused increased secretion of somatostatin which transiently antag¬ onized GRF action with the consequent fall in serum GH levels. The low GH levels would then remove somatostatin suppression of the somatotroph and once more allow full expression of the GH-releasing ability of GRF. Thus, in vivo, another aspect of soma¬ tostatin counter-regulation of GH secretion might be the prevention of somatotroph desensitization, at least in the short-term (24 h). To obtain direct evi¬ dence for this hypothesis we have determined the effect of somatostatin on GRF-induced desensitiz¬ ation in cultured rat pituitary cells. Under our experimental conditions somatostatin was able to partially attenuate the desensitizing action of GRF.
MATERIALS AND METHODS

Hormones
Growth hormone-releasing factor(l-40) was pur¬ chased from Bachern UK (Saffron Waiden, Essex) and stored at -20°C as a 10 pmol/1 solution, in phosphate-buffered saline (PBS; pH 7-4). Somatostatin(l-14) was purchased from Sigma Chemical Co. (Poole, Dorset) and stored at -20°C in PBS at 100 pmol/1. Tri-iodothyronine (T3) and dexa¬ methasone were also from Sigma and stored at 4°C as solutions of 1 mmol/1 in absolute ethanol. Calcium ionophore (A23187), dibutyryl cyclic 3':5'-monophosphate (dbcAMP) and bacitracin were from Sigma and forskolin was from Calbiochem (Cambridge). All other reagents were of analytical grade.
Radioimmunoassay (RIA) of GH
The GH content of medium and cells was measured by RIA, using reagents supplied by the National Hormone and Pituitary Agency, Baltimore, MA, U.S.A., as described previously (Clayton, Bailey, Abbot et al. 1986 ). All samples from one experiment were analysed in the same assay in which the intraassay coefficient of variation was between 5 and 10%.
Cell cultures and treatments
Pituitary cells from adult female rats were prepared by collagenase, DNase and hyaluronidase digestion as described in detail by Young, Naik & Clayton (1984 ) and A23187 (Young, Naik & Clayton, 1985) are effective GH secretagogues and are non-toxic to cells.
The results of these treatments are shown in Table 1 (pooled data from four or five experiments). In untreated cells the GH-releasing ability of 5 pmol forskolin/1 and 10 pmol A23187/1 was similar to that of lOnmol GRF/1. Fig. 3 . Untreated cells showed a 4-4-fold increase in GH release during the 4-h rechallenge period, while GRF-pretreated cells responded poorly (1-6 times basal). There was a dose-dependent attenuation of GRF-induced desensitization by somatostatin. With 1 pmol somatostatin/1 the absolute GH release on rechallenge with GRF was not significantly different from that of untreated cells, but the maximal/basal ratio (3 0) was reduced by virtue of the higher basal (unstimulated) release of GH from the somatostatin plus GRF-pretreated cells (Fig. 3) . Because a tenfold molar excess of somatostatin to GRF was most effec¬ tive at restoring GH responsiveness, 1 pmol somato¬ statin/1 was used in all subsequent experiments.
The results of another experiment where cells were exposed to increasing concentrations of GRF and a fixed concentration of somatostatin (1 pmol/1) for 4 h before rechallenge with 10 nmol GRF/1 are shown in Fig. 2b . Compared with cells pretreated with GRF alone (Fig. 2a) , absolute maximal and basal GH release on rechallenge with GRF was reduced by somatostatin in all groups. However, the maximal/ basal ratio was increased significantly (P<001) with the highest concentration of GRF used for pretreat¬ ment (100 nmol/1) which produced the most marked desensitization. In this experiment, somatostatin did not completely restore responsiveness to GRF.
Combined somatostatin (1 pmol/1) plus GRF (100 nmol/1) pretreatment was compared with GRF (100 nmol/1) pretreatment alone, using different cell preparations, four times for 4 h of exposure and three times for 18 h. The results, expressed as maximal/ basal ratio of GH release on rechallenge with GRF Somatostatin prevented the 50% reduction in cellu¬ lar GH content caused by pretreatment of cells with GRF (see above) and reduced the amount of GH released by GRF (100 nmol/1) during the pretreatment period by 39 + 5-3% (n = seven experiments).
As shown in Fig. 4 , somatostatin restored the sensitivity of GRF-pretreated cells to subsequent rechallenge with increasing concentrations of GRF, such that the ED50 concentration of GRF (0-25 nmol/1; GRF plus somatostatin) was the same as that for untreated control cells (0-3 nmol/1), as com¬ pared with 2 nmol/1 for cells pretreated with GRF alone.
DISCUSSION
These results confirm those of Bilezikjian & Vale (1984) and Ceda & Hoffman (1985) Ceda & Hoffman (1985) and 20-fold more than Bilezikjian & Vale (1984) . Furthermore, our cells were not as sensitive to GRF, since the ED50 concentration (0-3 nmol/1) was about tenfold higher than that reported previously (Bilezikjian & Vale, 1984; Harwood et al. 1984; Ceda & Hoffman, 1985 Smith, Perrin & Vale (1983) and by Young et al. (1985) for GnRH desensitization of gonadotrophs. Secondly, depletion of cellular GH by pretreatment with dbcAMP did not alter the ED50 concentration of GRF in subsequent dose-response studies (Bilezikjian & Vale, 1984) . Moreover, although not demonstrated here, but shown by Ceda & Hoffman (1985) (Clayton, 1982; Young et al. 1985) .
Uncoupling of the GRF receptor from adenylate cyclase is suggested by the data of Ceda & Hoffman (1985) , though Bilezikjian & Vale (1984) 
